| Dataset | DGIdb Drug Targets 2026 |
| Category | physical interactions |
| Type | drug |
| Description | A quinazoline compound having a 3-chloro-4-fluoroanilino group at the 4-position, a propenamido group at the 6-position, and a 3-morpholinopropoxy group at the 7-position. (Chemical Entities of Biological Interest Ontology, CHEBI_61399) |
| External Link | https://dgidb.org/results?searchType=drug&searchTerms=CANERTINIB |
| Similar Terms | |
| Downloads & Tools |
5 interacting proteins for the CANERTINIB drug from theDGIdb Drug Targets 2026 dataset.
| Symbol | Name | Standardized Value |
|---|---|---|
| BMX | BMX non-receptor tyrosine kinase | 1.41152 |
| ERBB2 | erb-b2 receptor tyrosine kinase 2 | 0.274259 |
| EGFR | epidermal growth factor receptor | 0.254656 |
| MTOR | mechanistic target of rapamycin (serine/threonine kinase) | 0.0598102 |
| YES1 | YES proto-oncogene 1, Src family tyrosine kinase | 0.0497014 |